Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Evgeniya Kuzmina"'
Publikováno v:
Астраханский вестник экологического образования. 19:124-130
Autor:
O. Novikova, Fedor Moiseenko, V. Chubenko, Oleg Gladkov, Alexey Tryakin, A. Fateeva, O. Pardabekova, S. Pelikh, L. Kindyalova, V. Petkau, Ekaterina Ignatova, N. Abduloeva, R. Shakirov, Mikhail Fedyanin, A. Kudryavtsev, E. Vorobeva, S. A. Tjulandin, Evgeniya Kuzmina, M. Lyadova
Publikováno v:
Annals of Oncology. 32:S140
Autor:
I. Stradaeva, Fedor Moiseenko, V. Chubenko, O. Novikova, A. Popova, Rashida Orlova, Anna V. Kudryavtseva, I. Popova, S. Beluhin, A S Zhabina, Evgeniya Kuzmina, A. Micshenko, M. Lyadova, Mikhail Fedyanin, A. Belonogov, H. Musaeva, Guzel Mukhametshina, A. Khasanova, Larisa Bolotina, Liubov Yu Vladimirova, B. Kertiev, S. A. Tjulandin
Publikováno v:
Annals of Oncology. 31:S184-S185
Autor:
Irina Chernyakova, Elena G. Ovchinnikova, Svetlana Protsenko, Tatiana Semiglazova, Evgeniya Kuzmina, Elena Karabina, Roman Smirnov, Roslercm, Ahmed Abdelgafur, Irina V. Evstigneeva, Evgeny Usynin, Natalia Kirdakova, Pavel Borisov, Dilorom Latipova, Magomed Aivazov, Alexei Kalpynsky, Anna Sergeevna Olshanskaya, Zurab Amoev, Olga Igorevna Samuseva, Ksenia Gennadievna Babina, Maria Volkova
Publikováno v:
Journal of Clinical Oncology. 38:644-644
644 Background: an assessment of efficacy and safety of lenvatinib in combination with everolimus in unselected patients with metastatic renal cell carcinoma (mRCC) progressed during or following ≥1 line of antiangiogenic targeted therapy. Methods:
Autor:
Olga Fakhrudinova, Alexandr Belonogov, Elena Karabina, Viacheslav Chubenko, Alfiya Khasanova, Fedor Moiseenko, Viktor Sherstnev, Polina Feoktistova, Guzel Mukhametshina, Irina Stradaeva, Larisa Bolotina, Sergei Tjulandin, Evgeniya Kuzmina, Mikhail Fedyanin, Hedi Musaeva, Andrey Micshenko, Rashida Orlova, Oksana Nekrasova, Liubov Yu Vladimirova, Olga Novikova
Publikováno v:
Journal of Clinical Oncology. 37:e15007-e15007
e15007 Background: Afl is one of the antiagiogenic agents used for the treatment for mCRC. Cardiovascular toxicity of Afl is shown to be a main reason of the drug discontinuation but there are no studies on factors associated with nonhem adverse even
Autor:
Alexey Tryakin, Rashida Orlova, Natalya Ulanova, Alexey Katkov, Liubov Yu Vladimirova, Evgeniya Kuzmina, Madina Ramazanova, Larisa Nikitina, Eduard Pshevlotskiy, Alexander V. Ivanov, Alexandra Tkachuk, Elena Matyushina, Valeriy Kulik, Sanal Erdniev, Sergei Tjulandin, Mikhail Fedyanin, Anton Yurievich Povyshev, Elena Smirnova, Shamai Aliyeva, Olga Shalofast
Publikováno v:
Annals of Oncology. 28:iii99
Autor:
Eduard Pshevlotskiy, Valeriy Kulik, Elena Smirnova, Sergei Tjulandin, Olga Shalofast, Alexandra Tkachuk, Mikhail Fedyanin, Evgeniya Kuzmina, Alexey Katkov, Liubov Yu Vladimirova, Elena Matyushina, Larisa Nikitina, Natalya Ulanova, Shamai Aliyeva, Alexander V. Ivanov, Madina Ramazanova, Rashida Orlova, Sanal Erdniev, Anton Yurievich Povyshev
Publikováno v:
Journal of Clinical Oncology. 35:e18022-e18022
e18022 Background: In Russia, there are no federal screening programs for detecting early stage of colon cancer; therefore we can assess the impact of various factors that could potentially affect the mortality of pts with mCRC Methods: We conducted
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.